8-K
MEDICINES CO /DE filed this form 8-K on 17 Feb 2016
- velhartice.info


Explanation of Adjustments:
(1)
Excludes share-based compensation of $6,475 and $8,073 for three months ended December 31, 2015 and December 31, 2014, respectively and $30,177 and $31,164 for the year ended December 31, 2015 and December 31, 2014, respectively.
(2) Excludes inventory adjustments.
(3)
Excludes amortization of intangible assets and other charges resulting from transactions with Nycomed, CSL, APP, Teva, Targanta and Rempex.
(4) Excludes upfront and milestone payments for research and development collaboration arrangements and manufacturing scale up for MDCO-216.
(5)
Excludes restructuring charges relating to the reorganization of our European operations of $7,159 in 2014.
(6)
Excludes changes in contingent purchase price due to shareholders of Targanta, Incline Therapeutics, Rempex and Annovation.
(7)
Excludes charges related to the acquisition of Tenaxis during 2014.
(8)
Excludes non-cash interest expense related to convertible senior notes.
(9)
Excludes investment impairment.
(10)
Excludes gain on sale of investment.
(11)
Excludes gain on remeasurement of our equity investment in Annovation.
(12)
Excludes gain from legal settlement in 2015 and impact of a one-time income in connection with the settlement with the former equity holders of Incline in 2014.
(13)
Net income tax adjustments reflect the estimated tax effect of the above adjustments and the impact of certain other non-operating tax adjustments.
(14)
Reflects impact of note hedge transactions on outstanding diluted share amounts and net income per share associated with convertible senior notes.


In addition to the financial information prepared in accordance with U.S. GAAP, this press release also contains adjusted financial measures that we believe provide investors and management with supplemental information relating to operating performance and trends that facilitate comparisons between periods and with respect to projected information. These adjusted measures should be considered in addition to, but not as a substitute for, the information prepared in accordance with U.S. GAAP. We typically exclude certain GAAP items that management does not believe affect our basic operations and that do not meet the GAAP definition of unusual or non-recurring items. Other companies may define these measures in different ways.

Page 9 of 9